［1］Michael C Wallace，David Preen，Gary P Jeffrey，et al.The evolving epidemiology of hepatocellular carcinoma：A global perspective［J］.Expert Rev Gastroenterol Hepatol，2015，9(6)：765-779.
[2]Liu Guoqi，Wu Xiangwei，Yang Hongqiang，et al.Prognostic factors of TACE treatment in patients with primary hepatic carcinoma［J］.Modern Oncology，2016，24(02)：267-270.［刘国起，吴向未，杨宏强，等.肝动脉化疗栓塞治疗原发性肝癌的预后因素分析［J］.现代肿瘤医学，2016，24(02)：267-270.］
[3]Josep M Llovet，Maria Isabel Real，Xavier Montaa，et al.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma：A randomised controlled trial［J］.Lancet，2002，359(9319)：1734-1739.
[4]Jia ZZ，Feng YL，Shi HB.Correlation between serum HIF-1α and VEGF level pre-and post-TACE in patients with primary liver cancer［J］．Chin J Interv Imaging Ther，2010，7(2)：117-120.［贾中芝，冯耀良，施海彬.原发性肝癌TACE前后血清HIF-1α与VEGF的相关性［J］.中国介入影像与治疗学，2010，7（2)：117-120.］
[5]Zheng PX，Shu RY，Zhao YL，et al.Association between vascular endothelial growth factor and metastasis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma［J］.Hepatobiliary Pancreat Dis Int，2004，3(3)：386-390.
[6]Covello KI，Simon MC，Keith B．Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia inducible factor-2alpha knock-in allele promotes tumor growth［J］．Cancer Res，2005，65(6)：2277-2286.
[7]Chen Jie，Hou Encun.Progress of VEGF and its receptors in HCC angiogenesis and antiangiogenesis therapy［J］.Modern Oncology，2016，24(03)：498-502.［陈杰，侯恩存.VEGF及其受体与肝细胞癌血管生成和抗血管治疗研究进展［J］.现代肿瘤医学，2016，24(03)：498-502.］
[8]Hu ZD，Yang AL，Su GZ，et al.Huaier restrains proliferative and invasive potential of human hepatoma SKHEP-1 cells partially through decreased Lamin B1 and elevated NOV［J］.Sci Rep，2016，6：31298.
[9]Li C，Zheng XL，Peng L，et al.Anticancer effect of PS-T on the experimental hepatocellular carcinoma［J］.Chinese-German Journal of Clinical Oncology，2004，3(1)：55-59.
[10]Li C，Wu X，Zhang HH，et al.A Huaier polysaccharide restrains hepatocellular carcinoma growth and metastasis by suppression angiogenesis［J］.Int J Biol Macromol，2015，75：115-120.
[11]Xu X，Wei Q，Wang K，et al.Anticancer effects of Huaier are associated with down regulation of p53［J］.Asian Pac J Cancer Prev，2011，12(9)：2251-2254.
[12]Wang P，Zhoug W.Protective effect of Huaier granules on immune function after TACE in patients with liver cancer［J］.China Modern Doctor，2013，51(36)：58-60.［汪平，仲炜.槐耳颗粒对肝癌栓塞化疗后免疫功能的影响［J］.中国现代医生，2013，51(36)：58-60.］
[13]Hu ZD，Yang AL，Fan HT，et al.Huaier aqueous extract sensitizes cells to rapamycin and cisplatin through activating mTOR signaling［J］.J Ethnopharmacol，2016，186：143-150.
[14]Yu Z，Wu T.The reversal effects of Trametes robiniophila Murr.on multidrug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU［J］.Journal of Oncology，2013，19(6)：443-447.［喻喆，吴涛．槐耳清膏体外逆转人肝癌耐药细胞BEL-7402/5-FU多药耐药性［J］.肿瘤学杂志，2013，19(6)：443-447.］
[15]Wu H.Huaier granules combined with chemoembolization in treating primary liver cancer in 96 cases［J］.China Pharmaceuticals，2014，23(3)：16-18.［吴晖.槐耳颗粒联合化疗栓塞术治疗原发性肝癌96 例［J］.中国药业，2014，23(3)：16-18.］
[16]Li JD，Peng Y，Dai Y.Clinical effects of Huaier and transarterial chemoembolization (TACE) in treatment of advanced hepatocellular carcinoma［J］.Med J West China，2010，22(3)：418-420.［李敬东，彭勇，戴毅.槐耳颗粒联合肝动脉灌注化疗栓塞治疗晚期肝癌的临床研究［J］.西部医学，2010，22(3)：418-420.］
[17]Li M，Shi JP，Yu HH.Relationship between the ' Real World' research，randomized controlled trial and number of one randomized controlled trial in clinical therapeutic study［J］.Chin J Epidemiol，2012，33(3)：342-345.［李敏，时景璞，于慧会.真实世界研究与随机对照试验、单病例随机对照试验在临床治疗性研究中的关系比较［J］.中华流行病学杂志，2012，33(3)：342-345.］
[18]Silverman SL.From randomized controlled trials to observational studies［J］.Am J Med，2009，122：114-120.
[19]Ye SL，Chen XP，Yang JM.Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma：Final outcome from the chinese patient subset of the GIDEON study［J］.Oncotarget，2015，7(6)：6639-6648.
[20]Song XJ，Li YM，Zhang HW，et al.The anticancer effect of Huaier (review)［J］.Oncol Rep，2015，34(1)：12-21.